Literature DB >> 29931497

Impact of PAP therapy on hospitalization rates in Medicare beneficiaries with COPD and coexisting OSA.

Gurinder Singh1, Amitesh Agarwal2, Wei Zhang2,3, Yong-Fang Kuo3,4, Rizwana Sultana2, Gulshan Sharma2,4.   

Abstract

OBJECTIVE: Growing evidence supports that patients with chronic obstructive pulmonary disease (COPD) and coexisting obstructive sleep apnea (OSA) have poor prognosis. This association is described as overlap syndrome. Positive airway pressure (PAP) therapy is now the preferred treatment for OSA. We hypothesized that use of PAP therapy in elderly patients with overlap syndrome would be associated with lower healthcare utilization.
METHODS: In this retrospective cohort study, we analyzed data from 5% national sample of fee-for-service Medicare beneficiaries with a diagnosis of COPD who were newly started on PAP therapy in 2011. We examined the effect of PAP therapy on emergency room (ER) visits and hospitalizations for all-cause and COPD-related conditions in the 1 year pre- and 1 year post-initiation of PAP therapy.
RESULTS: In year 2011, we identified 319 patients with overlap syndrome who were new users of PAP therapy. In this cohort of patients, hospitalization rates for COPD-related conditions were significantly lower in the 1 year post-initiation of PAP therapy compared to the 1-year pre-initiation period (19.4 vs 25.4%, P value = 0.03). However, ER visits (for any cause or COPD-related conditions) and hospitalization rates for any cause did not differ significantly in the pre- and post-initiation periods. PAP therapy was more beneficial in older adults, those with higher COPD complexity, and those with three or more comorbidities.
CONCLUSION: Initiation of PAP therapy in elderly patients with overlap syndrome is associated with a reduction in hospitalization for COPD-related conditions, but not for all-cause hospitalizations and ER visits.

Entities:  

Keywords:  COPD; Hospitalization and healthcare utilization; OSA; Overlap syndrome; PAP

Mesh:

Substances:

Year:  2018        PMID: 29931497      PMCID: PMC6309578          DOI: 10.1007/s11325-018-1680-0

Source DB:  PubMed          Journal:  Sleep Breath        ISSN: 1520-9512            Impact factor:   2.816


  28 in total

1.  High Prevalence of Obstructive Sleep Apnea in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease.

Authors:  Xavier Soler; Eduardo Gaio; Frank L Powell; Joe W Ramsdell; Jose S Loredo; Atul Malhotra; Andrew L Ries
Journal:  Ann Am Thorac Soc       Date:  2015-08

Review 2.  Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome?

Authors:  S Ryan; C T Taylor; W T McNicholas
Journal:  Thorax       Date:  2009-07       Impact factor: 9.139

3.  Characteristics of hospitals receiving penalties under the Hospital Readmissions Reduction Program.

Authors:  Karen E Joynt; Ashish K Jha
Journal:  JAMA       Date:  2013-01-23       Impact factor: 56.272

4.  Airway and alveolar nitric oxide measurements in obstructive sleep apnea syndrome.

Authors:  A M Fortuna; R Miralda; N Calaf; M González; P Casan; M Mayos
Journal:  Respir Med       Date:  2011-01-12       Impact factor: 3.415

5.  Sleep apnea testing and outcomes in a large cohort of Medicare beneficiaries with newly diagnosed heart failure.

Authors:  Shahrokh Javaheri; E Ben Caref; Er Chen; Kuo Bianchini Tong; William T Abraham
Journal:  Am J Respir Crit Care Med       Date:  2010-07-23       Impact factor: 21.405

6.  Association of chronic obstructive pulmonary disease and sleep apnea syndrome.

Authors:  A Chaouat; E Weitzenblum; J Krieger; T Ifoundza; M Oswald; R Kessler
Journal:  Am J Respir Crit Care Med       Date:  1995-01       Impact factor: 21.405

7.  Sleep and sleep-disordered breathing in adults with predominantly mild obstructive airway disease.

Authors:  Mark H Sanders; Anne B Newman; Catherine L Haggerty; Susan Redline; Michael Lebowitz; Jonathan Samet; George T O'Connor; Naresh M Punjabi; Eyal Shahar
Journal:  Am J Respir Crit Care Med       Date:  2003-01-01       Impact factor: 21.405

8.  Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data.

Authors:  Douglas W Mapel; Michael P Dutro; Jeno P Marton; Kimberly Woodruff; Barry Make
Journal:  BMC Health Serv Res       Date:  2011-02-23       Impact factor: 2.655

9.  Obstructive sleep apnea, COPD, the overlap syndrome, and mortality: results from the 2005-2008 National Health and Nutrition Examination Survey.

Authors:  Wei Du; Jun Liu; Jianlong Zhou; Dan Ye; Yan OuYang; Qingnan Deng
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-02-27

10.  Airway and systemic inflammation and decline in lung function in patients with COPD.

Authors:  Gavin C Donaldson; Terence A R Seemungal; Irem S Patel; Angshu Bhowmik; Tom M A Wilkinson; John R Hurst; Peter K Maccallum; Jadwiga A Wedzicha
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

View more
  4 in total

1.  Obstructive Sleep Apnea with Chronic Obstructive Pulmonary Disease among Medicare Beneficiaries.

Authors:  Peter Starr; Amitesh Agarwal; Gurinder Singh; Enshuo Hsu; Wei Zhang; Yong-Fang Kuo; Carl Boethel; Gulshan Sharma
Journal:  Ann Am Thorac Soc       Date:  2019-01

Review 2.  Review of the prevalence, pathogenesis and management of OSA-COPD overlap.

Authors:  M Brennan; M J McDonnell; S M Walsh; F Gargoum; R Rutherford
Journal:  Sleep Breath       Date:  2022-01-16       Impact factor: 2.816

3.  Accuracy of WatchPAT for the Diagnosis of Obstructive Sleep Apnea in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  R Jen; J E Orr; Y Li; P DeYoung; E Smales; A Malhotra; R L Owens
Journal:  COPD       Date:  2020-01-22       Impact factor: 2.409

4.  Association of Opioid and Benzodiazepine Use with Adverse Respiratory Events in Older Adults with Chronic Obstructive Pulmonary Disease.

Authors:  Jacques Baillargeon; Gurinder Singh; Yong-Fang Kuo; Mukaila A Raji; Jordan Westra; Gulshan Sharma
Journal:  Ann Am Thorac Soc       Date:  2019-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.